Premium
Combined treatment with angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers to prevent end‐stage kidney disease in patients who do not have diabetes
Author(s) -
Strippoli Giovanni FM,
Jonathan Craig C
Publication year - 2004
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2004.tb06375.x
Subject(s) - medicine , excellence , kidney disease , nephrology , family medicine , political science , law
Participants: 263 patients (mean age about 45 years; 54% non-diabetic biopsy-proven renal disease, impaired rena (creatinine clearance rate, 20–70 mL/min), persistent prot > 0.3 g/24 h, and hypertension. Patients with proteinuria > Trial: Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.